NCT07663279Not yet recruiting
BicMag Study - Improving Mineral Buffering Capacity in Dialysis Patients
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
The BicMag study is a prospective, randomized, controlled cross-over study that aims to examine the potential additive effect of a dialysate enriched with both bicarbonate and magnesium on mineral buffering capacity in the blood of chronic hemodialysis patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 91 (estimated)
- First submitted
- 17 Jun 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2029
- Lead sponsor
- Elisabethinen Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT07663279
What you commit to
- Study type: Interventional
- Planned participants: 91
- From Oct 2026 to the primary completion date, Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently participating in another investigational device or drug study or non-interventional study
- Elective living-donor kidney transplant scheduled during the study period
- Therapy with bisphosphonates within the past 12 months or denosumab within the past 6 months
Lab values
- Dialysate calcium other than 1.25 mmol/l
Other
- Inability to provide informed consent
- Parathyroidectomy planned during the study
- Pregnant or nursing (lactating) women
Who the study is looking for
- Age ≥ 18 years
- Prevalent patients (≥ 3 months) treated with thrice weekly hemodialysis or hemodiafiltration
- Dialysate calcium of 1.25 mmol/l
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.